The quarter beat on scale but missed on adjusted earnings. Published consensus was approximately $596.5 million of revenue and $0.21 of adjusted EPS; Privia delivered $632.6 million and $0.19, respectively. Revenue was therefore about 6% ahead, while adjusted diluted EPS was about 10% below expectations.
| Metric | Q2 2026 | Q2 2025 | Change | Market expectation |
|---|---|---|---|---|
| Revenue | $632.6M | $521.2M | +21.4% | ~$596.5M |
| Adjusted diluted EPS | $0.19 | $0.17 | +11.8% | ~$0.21 |
| Adjusted EBITDA | $37.4M | $29.0M | +29.1% | — |
| Attributed lives | 1.647M | 1.382M | +19.2% | — |
| Platform contribution margin | 52.2% | 49.9% | +230 bps | — |
Underlying operating growth remained strong. Attributed lives rose 19.2%, practice collections increased 12.4%, and platform contribution grew 20.1%, with platform contribution margin expanding to 52.2% from 49.9% (Key Metrics and Non-GAAP Financial Measures). Adjusted EBITDA grew faster than revenue, up 29.1% (Financial Highlights; Platform Contribution and Adjusted EBITDA reconciliation). That supports a stronger operating picture than the EPS miss alone suggests.
Management raised the most important growth assumptions for 2026. The attributed-lives target increased to 1.625–1.650 million from 1.550–1.600 million, while practice collections and GAAP revenue moved to the high end of prior ranges. Care margin, platform contribution, and adjusted EBITDA were raised to the midpoint-to-high end, while implemented-provider guidance was unchanged (FY 2026 Guidance). This is a real change to the forward outlook, not merely a reaffirmation.
| FY 2026 guidance | Initial range | Updated guidance | Change |
|---|---|---|---|
| Attributed lives | 1.550M–1.600M | 1.625M–1.650M | Raised |
| Practice collections | $3.650B–$3.750B | High end | Raised to high end |
| GAAP revenue | $2.350B–$2.450B | High end | Raised to high end |
| Care margin | $515M–$530M | Mid-to-high end | Raised qualitatively |
| Platform contribution | $260M–$270M | Mid-to-high end | Raised qualitatively |
| Adjusted EBITDA | $145M–$155M | Mid-to-high end | Raised qualitatively |
Cash conversion is the main blemish beneath the headline growth. Operating cash flow was negative $48.4 million in the first half versus negative $16.1 million a year earlier, driven largely by a $172.4 million increase in accounts receivable (Cash Flow statement). Cash still stood at $412.2 million at June 30, but the widening receivables balance means the strong reported revenue has not yet translated into cash as cleanly as the income statement implies.
Net read: modestly better than expected, but not a clean beat. The revenue outperformance and raised full-year operating outlook outweigh the adjusted-EPS shortfall, while the cash-flow drag limits the strength of the signal. The filing reshapes expectations upward for growth and operating scale, but less decisively for near-term per-share earnings quality.
Read the original 8-K on SEC EDGAR ↗